Attorney Michel Brady Lynch, Esq. of The Michael Brady Lynch Firm in Winter Park will speak on September 16 in Ft. Lauderdale at Mass Tort Nexus’ highly regarded Four Day Immersion Course. Attorney Lynch has prepared a deep-dive into Pradaxa and Xarelto litigations. This course unites attorneys from all over the United States to hear leaders in the industry discuss innovative tactics and the latest litigation developments.
“Mass Tort Nexus is unlike any other attorney education program in the country,” said Attorney Lynch. “Their immersion course is far more than just a seminar, it is the gold standard for mass torts practice education hands down.”
About Michael Brady Lynch
Michael Brady Lynch is the founder and lead trial attorney for The Michael Brady Lynch Firm. For over 20 years as a trial attorney, he has been a passionate consumer advocate for victims and their families.
Not only is Michael Brady Lynch fervent about justice, but also holds leadership positions in numerous State and Federal mass tort products liability actions, including:
- Plaintiff’s Steering Committee (“PSC”) of In re Pradaxa Products Liability Litigation MDL #2385, which resulted in a global settlement of claims in excess of $650 million.
- Plaintiff’s Executive Committee (PEC) in California coordinated Pradaxa litigation JCCP 4863, ongoing litigation representing victims of Pradaxa uncontrollable bleeding events post-MDL settlement.
- Plaintiff’s Leadership Committee (“PLC”) of In re Pradaxa Connecticut State Court Consolidated Proceeding, ongoing litigation representing victims of Pradaxa uncontrollable bleeding events post-MDL settlement.
- Plaintiff’s Steering Committee (“PSC”) of In re Viagra Products Liability Litigation MDL #2691, representing victims of melanoma associated with the erectile dysfunction drug Viagra.
- Bellwether Committee for In re Xarelto Products Liability Litigation MDL #2592, responsible for the analysis and selection of trial cases in the Xarelto MDL.
Your Blood Thinner Litigation Attorney
Approved by the FDA in October 2010 to prevent strokes in patients with atrial fibrillation, Pradaxa was the first blood thinner to compete with the longtime treatment of warfarin (brand names Coumadin and Jantoven). Just over a year later, research began to emerge, linking Pradaxa to serious bleeding risks that were not communicated to patients.
In December 2011, The Food and Drug Administration (FDA) issued a safety announcement regarding the bleeding incidents reported for patients taking Pradaxa. The FDA notes such bleeding risks are serious and have proven deadly. Later, in November 2014, The Journal of the American Medical Association (JAMA) reported that Pradaxa is associated with a 30% greater risk of a bleeding event, a 58% greater risk of major bleeding, and 85% greater risk of gastrointestinal bleeding.
The reports resulted in thousands of lawsuits against the maker of Pradaxa for victims of uncontrollable bleeding events. The lawsuits were spearheaded by Michael Brady Lynch and a select group of mass tort attorneys from around the country.
Attorney Lynch was a member of the Plaintiff’s Steering Committee in the Pradaxa Multi-District Litigation and instrumental in securing the $650 million settlement for those injured by Pradaxa’s uncontrollable bleeding. He continues to be a leader in blood thinner litigation nationwide in representing those who continue to suffer uncontrollable bleeding events from Pradaxa or Xarelto.
Xarelto has brought similar issues to patients. It came on the market in 2011 to reduce the risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and blood clots. Manufacturers Bayer and Janssen promoted the drug has the gold standard for anticoagulants. However, it may be more dangerous than other medications on the market since there was not an antidote until May 2018.
Attorney Lynch has said, “The U.S. numbers for Pradaxa and Xarelto bleeding events are truly staggering. It is on the verge of a national health disaster.”
To register for this course to learn more about Pradaxa and Xarelto litigations, or for additional information on Mass Tort Nexus and future courses, please click the link to navigate to their website.
